EarliPoint Health

Most ABA providers sit downstream. They wait for diagnoses. They wait for referrals. But the ones growing fastest? They’ve become the front door for autism care. By integrating a quick, objective assessment into intake, they’re engaging families earlier—without adding clinicians. It’s not about becoming a diagnostic center. It’s about owning the first step.

Quick question: How many of your best early-age cases never make it to you? Not because of marketing… …but because diagnosis took too long? Some clinics are helping families earlier in the journey—using a objective assessments to accelerate diagnosis. The result can lead: • Younger clients • Stronger pipeline • Less competition

Scaling ABA is hard. Not because of therapy capacity… …but because diagnostic capacity doesn’t scale. You can’t just hire more specialists. Some multi-site groups are solving this with a standardized, technician-run assessment across locations. → ~12 minutes → FDA-cleared → No added specialist headcount And it creates consistency across sites.

You don’t have a demand problem. You have a diagnosis bottleneck. We keep hearing: • Long waitlists • Delayed diagnoses • Lost referrals Which leads to: → Older client mix → Underfilled hours Some clinics are solving this with a quick, technician-run assessment at intake. No added headcount. Just a smarter front door.

Most ABA clinics don’t lose clients because of bad marketing. They lose them because they meet families too late. The clinics pulling ahead are moving upstream—closer to diagnosis. With a quick, staff-run assessment, they’re getting younger clients earlier and filling schedules faster. Simple shift. Big impact.

📣 You’ve been watching. You’ve been asking.📣 Now we can share why. EarliPoint has received expanded FDA clearance, extending the use of our diagnostic assessment device to children up to age 8. This matters because thousands of children between ages 3 and 7 have had limited access to objective, technology-aided autism assessments. Families have waited, and with this expansion, more children can now benefit from EarliPoint during some of the most important developmental years of their lives. To our team, thank you. This milestone belongs to every one of you. To the clinicians, families, and partners who have been part of this journey, this is for you. We’re just getting started. Indication for Use: The EarliPoint Assessment device is indicated as a tool to aid qualified clinicians in the diagnosis and assessment of Autism Spectrum Disorder (ASD) in children ages 16 months through 95 months (7 years), who are at risk based on concerns identified by a parent, caregiver, or healthcare provider.